ProlongedSARS-CoV-2 Infection With Common Features in Two Patients Receiving Anti-CD20 Therapy
| Autor: | PAPANIKOLOPOULOU, AMALIA, THIMIS, VASILIS, ANTONOGIANNAKI, EIRINI, RAPTI, VASILIKI, TSIAKOS, KONSTANTINOS, KRALLIS, GIANNIS, NTOURAKI, SOFIA, KOKKOTIS, GEORGIOS, PANAGIOTOU, EMMANOUIL, SAKKA, VISSARIA, KAKALOU, ELENI, NITSOTOLIS, THOMAS, POULAKOU, GARYPHALLIA, SYRIGOS, KONSTANTINOS N. |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | In Vivo |
| ISSN: | 1791-7549 0258-851X |
| DOI: | 10.21873/invivo.13100 |
| Popis: | Background/Aim: Anti-CD20-depleting monoclonal antibodies predispose patients to the development of severe disease of SARS-CoV-2 infection. These antibodies are given as backbone or maintenance therapy in patients with hematological malignancies and rheumatology diseases, inducing effective B-cell depletion along with antibody-dependent cell-mediated cytotoxicity (ADCC) and disrupting infection-protective antibody responses. Case Report: We describe two cases of prolonged SARS-CoV-2 infection with common features, in two patients receiving anti-CD20 therapies, the first for chronic lymphocytic leukemia (CLL) and the second for rheumatoid arthritis (RA). For CLL patient, despite administration of antiviral therapy, signs and symptoms of SARS-CoV-2 infection persisted for 43 days, with resolution and lymphocyte recovery from day 33. For RA patient, despite administration of two courses of antiviral therapy, signs and symptoms of SARS-CoV-2 infection persisted for 47 days, without resolution and lymphocyte recovery, leading to a fatal outcome due to acute respiratory distress syndrome (ARDS) and unspecified sepsis. Conclusion: These two cases highlight the risk for persistent SARS-CoV-2 infection in patients treated with anti-CD20 monoclonal antibodies and support a role for cellular immunity recovery for disease control. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|